The complex relation between bisphosphonate adherence and fracture reduction

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 7, 2010, Pages 3251-3259

  Patrick, Amanda R ^a   Brookhart, M Alan ^a   Losina, Elena ^a   Schousboe, John T ^c   Cadarette, Suzanne M ^b   Mogun, Helen ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; COHORT ANALYSIS; COMMUNITY LIVING; FEMALE; FOREARM FRACTURE; FRACTURE REDUCTION; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; VERTEBRA FRACTURE; FRACTURE; HEALTH SURVEY; PREVALENCE; REGRESSION ANALYSIS; RISK; STATISTICS; UNITED STATES;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HEALTH SURVEYS; HUMANS; MALE; MEDICATION ADHERENCE; OSTEOPOROSIS; PENNSYLVANIA; PREVALENCE; REGRESSION ANALYSIS; RISK; RISK FACTORS;

EID: 77954934019     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2778     Document Type: Article

References (26)

1. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A 2007 Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22:465-475 (Pubitemid 46797130)
2. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-578
3. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ 2007 Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493-1501 (Pubitemid 350211697)
4. Ström O, Borgström F, Kanis JA, Jönsson B 2009 Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20:23-34
5. Hughes DA, Bagust A, Haycox A, Walley T 2001 The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 10:601-615 (Pubitemid 32998372)
6. Adachi J, Lynch N, Middelhoven H, Hunjan M, Cowell W 2007 The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet Disord 8:97
7. Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E 2008 Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 23:1435-1441
8. Schneeweiss S, Wang PS, Avorn J, Glynn RJ 2003 Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res 38:1103-1120 (Pubitemid 37048302)
9. Deyo RA, Cherkin DC, Ciol MA 1992 Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619
10. Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM, Solomon DH 2007 Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 166:348-354 (Pubitemid 47216808)
11. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082
12. Baron JA, Lu-Yao G, Barrett J, McLerran D, Fisher ES 1994 Internal validation of Medicare claims data. Epidemiology 5:541-544 (Pubitemid 24271624)
13. Ray WA, Griffin MR, Fought RL, Adams ML 1992 Identification of fractures from computerized Medicare files. J Clin Epidemiol 45: 703-714
14. Curtis JR, Mudano AS, Solomon DH, Xi J, Melton ME, Saag KG 2009 Identification and validation of vertebral compression fractures using administrative claims data. Med Care 47:69-72
15. Curtis JR, Taylor AJ, Matthews RS, Ray MN, Becker DJ, Gary LC, Kilgore ML, Morrisey MA, Saag KG, Warriner A, Delzell E 2009 "Pathologic" fractures: should these be included in epidemiologic studies of osteoporotic fractures? Osteoporos Int 20:1969-1972
16. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK 2008 Medication compliance and persistence: terminology and definitions. Value Health 11:44-47 (Pubitemid 351160875)
17. R Development Core Team 2005 R: A language and environment for statistical computing, reference index version 2.2.1. Vienna: R Foundation for Statistical Computing
18. Robertson T, Wright FT and Dykstra RL 1988 Order restricted statistical inference. New York: Wiley
19. Briesacher BA, Andrade SE, Yood RA, Kahler KH 2007 Consequences of poor compliance with bisphosphonates. Bone 41:882-887
20. Weycker D, Macarios D, Edelsberg J, Oster G 2007 Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 18:271-277 (Pubitemid 46233172)
21. Blouin J, Dragomir A, Moride Y, Ste-Marie LG, Fernandes JC, Perreault S 2008 Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br J Clin Pharmacol 66:117-127 (Pubitemid 351822168)
22. Huybrechts KF, Ishak KJ, Caro JJ 2006 Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922-928
23. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM 2008 Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511-517
24. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022 (Pubitemid 44175011)
25. Curtis J, Larson J, Delzell E, Judd S, Safford MM, LaCroix A, Chlebowski R 2009 Does the benefit of medication adherence relate more to a drug effect or the behavior itself? Quantifying the effect of adherence behavior using data from the placebo arm of the WHI. Arthritis Rheum 60:613
26. Cadarette S, Solomon D, Katz J, Patrick A, Brookhart M 2010 Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Can J Clin Pharmacol 17:e92 (Abstract)